Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07421739 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Choroidal Melanoma Patient-Reported Outcome Study (CM-PRO) in a Subset of AU-011-301 (CoMpass) Subjects

StatusActive, Not Recruiting
PhaseNot specified
Started
View on ClinicalTrials.gov ↗
Trial flagged as At Risk
Primary endpoint reworded 1 of 1 changed
See other at-risk trials from Aura Biosciences

Record History

See every version on ClinicalTrials.gov ↗

  1. Primary endpoint(s) modified Show 6 more changesShow less
    • Enrollment closed, study ongoing
    • Interventions modified
    • Eligibility criteria shortened, about 8 words
    • Secondary endpoint revised
    • Study description expanded, about 14 words
    • Site details revised
  2. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Aura Biosciences
6 trials monitored
See 1 trial at risk
Melanoma
1,092 trials monitored
See 60 trials at risk
To assess subject-centric evidence of QoL outcomes in a subset of subjects enrolled in the global Phase 3 AU-011-301 clinical trial.
Trial Details
NCT Number NCT07421739
Lead Sponsor Aura Biosciences
Collaborators: Vitaccess Ltd
Conditions
(from sponsor)		 Choroidal Melanoma, Indeterminate Lesions, Uveal Melanoma, Ocular Melanoma
Related terms Eye Neoplasms, Uveal Melanoma
Enrollment 15 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov